Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?

Key Takeaways CRSP's CTX310 showed up to 86% LDL and 82% TG reductions in early-stage study data.CRSP is developing CTX320 in an early-stage study for lipoprotein(a), tied to heart disease.The company plans to advance CTX340 and CTX450 into clinical studies by the end of 2025.CRISPR Therapeutics (CRSP) is the first and only company in the world to market a CRISPR/Cas9-based therapy. The company tasted major success with the approval of its one-shot gene therapy, Casgevy, in late 2023 and early 2024 across t ...